Purpose
To evaluate the ability of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), aspartate aminotransferase-to-lymphocyte ratio (ALRI) and systemic-inflammation index (SII) to predict clinical outcomes in hepatocellular carcinoma (HCC) patients undergoing transarterial radioembolization (TARE).
Materials and Methods
One hundred forty-five patients who underwent treatment of 167 HCCs had their pretreatment and 1 month post treatment laboratory values evaluated. Overall survival (OS), progression-free survival (PFS) and local PFS models were performed with patients separated by median inflammatory scores.
Results
The median pretreatment NLR, PLR, ALRI and SII were 3.0 (range: 0.5–176), 104.4 (range: 25–830), 55.7 (range: 7.5–2090) and 360.2 (range: 51.1–7207.8), respectively. While the median post treatment NLR, PLR, ALRI and SII were 6.2 (range: 0.4–176), 180 (range: 35–2100), 125 (range: 15.9–5710) and 596.8 (range: 28.9–19,320), respectively. OS models showed significant differences when separating the groups by median post treatment NLR (p = 0.003) and SII (p = 0.003). Multivariate Cox regression models for OS with all pre and post treatment inflammatory markers (log-scale) as well as tumor size, AFP and Child–Pugh score showed significant pretreatment NLR [HR: 0.22 (95% CI:0.06–0.75), p = 0.016] and SII [3.52 (95% CI: 1.01–12.3), p = 0.048], as well as post treatment NLR [6.54 (95% CI: 1.57–27.2), p = 0.010] and SII [0.20 (95% CI: 0.05–0.82), p = 0.025] association. The post treatment ALRI (p = 0.010) correlated with PFS while, post treatment NLR (p < 0.001), ALRI (p = 0.024) and SII (p = 0.005) correlated with local PFS.
Conclusion
Pretreatment and post treatment NLR and SII may be associated with OS and post treatment ALRI may be associated with both PFS and local PFS in HCC patients undergoing TARE.
